Jounce Therapeutics is a clinical-stage immunotherapy company that aims for cancer treatment. With a focus on the development of vopratelimab, a monoclonal antibody, and JTX-8064, an antibody for leukocyte immunoglobulin-like receptor B2, it aims to treat solid tumors and macrophages. Jounce Therapeutics was founded in 2012 and is headquartered in Cambridge, Massachusetts.